FindTrial
Sign In

Maintenance chemotherapy

DRUG5 trials

Sponsors

AIO-Studien-gGmbH, University of Texas Southwestern Medical Center, Universitätsklinikum Hamburg-Eppendorf, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, University Hospital Ostrava

Conditions

Brain TumorsMetastatic Colorectal CancerNon Small Cell Lung CancerRadiotherapyStage IV Non-Small Cell Lung Cancer

Phase 2

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
CompletedNCT01991873
AIO-Studien-gGmbHMetastatic Colorectal Cancer
Start: 2014-04-30End: 2023-02-18Updated: 2023-06-15
Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial
CompletedNCT02045446
University of Texas Southwestern Medical CenterStage IV Non-Small Cell Lung Cancer
Start: 2014-02-28End: 2022-05-02Updated: 2023-05-23
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
Active, not recruitingNCT02066220
Universitätsklinikum Hamburg-EppendorfBrain Tumors
Start: 2014-06-30End: 2026-12-31Target: 360Updated: 2025-12-04
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer
NCT03142282
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMetastatic Colorectal Cancer, Radiotherapy
Start: 2019-01-01End: 2024-08-31Target: 200Updated: 2018-09-07

Unknown Phase

SBRT/RT in Oligometastatic Stage IV NSCLC
RecruitingNCT05647590
University Hospital OstravaNon Small Cell Lung Cancer
Start: 2019-10-01End: 2025-12-31Target: 10Updated: 2024-01-30

Related Papers

Prognostic and predictive value of baseline derived neutrophil-to-lymphocyte ratio (dNLR) in <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC) receiving 5-fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab) maintenance: A post-hoc analysis of the PANAMA/AIO KRK 0212) trial.
Journal of Clinical Oncology2026-05-28
Data from Deep Learning–Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer
2026-03-02
&lt;SPAN style="font-weight: 400;"&gt;Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer&lt;/SPAN&gt;.
2026-01-05
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer.
2025-11-18
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.
2025-10-011 citations
Data from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025-10-01
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
2025-08-28
Impact of anti-EGFR and anti-VEGF antibodies on survival in BRAF <sup>V600E</sup> mutated metastatic colorectal cancer: A pooled analysis of eight clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
Journal of Clinical Oncology2025-05-28
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial.
2024-12-161 citations
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.
2024-07-132 citations
FU/FA maintenance therapy with or without panitumumab (pmab) in <i>RAS</i> wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.
Journal of Clinical Oncology2024-06-011 citations
Dermatology-related quality of life outcomes in patients with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: A prespecified secondary analysis of the phase 2 randomized PanaMa (AIO KRK 0212) trial.
Journal of Clinical Oncology2024-06-01
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
2023-06-286 citations
Impact of number and size of colorectal metastases (CRM) on survival in patients with<i> RAS</i> wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212).
Journal of Clinical Oncology2023-06-01
Size-related heterogeneity of colorectal liver metastases (CRLM) in patients with advanced <i>RAS</i> wild-type metastatic colorectal cancer (mCRC) treated in the PanaMa trial: Implication for treatment decisions.
Journal of Clinical Oncology2023-06-01
Health-related quality of life in patients with <i>RAS</i> wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212).
Journal of Clinical Oncology2023-01-24
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic CRC: Analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Journal of Clinical Oncology2023-01-24
RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer
Gastroenterology report2022-12-308 citations
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
2022-10-255 citations
Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).
Journal of Clinical Oncology2022-06-01

7 more papers not shown